Koenig Sheldon L. 4

What Happened

• Sheldon L. Koenig, President, CEO and Director of Esperion Therapeutics (ESPR), was granted a total of 1,371,220 shares on 2026-03-13 via two award entries: 723,760 shares (direct award) and 647,460 shares classified as derivative awards. Both grants show a $0.00 acquisition price (compensation awards), so no cash was paid by the insider.

Key Details

• Transaction date: March 13, 2026; Form 4 filed March 16, 2026 (filed within SEC’s 2-business-day window).
• Grants: 723,760 shares (award) and 647,460 shares (derivative award); total 1,371,220 shares; acquisition price reported $0.00.
• Vesting: The award will vest over four years in equal quarterly installments; first vesting date is June 15, 2026 (footnote F1).
• Footnote F2: filing notes inclusion of 3,930 shares recently acquired under Esperion’s Employee Stock Purchase Plan (this relates to reported holdings).
• The derivative-classified grant likely represents restricted stock units or similar time-based equity that vests rather than immediate issuance of free shares.

Context

• This is a compensation grant (award), not an open-market buy or sale, and thus reflects executive compensation rather than a direct market signal. Vesting schedule means the shares will be earned over time; they are not immediately liquid holdings that were purchased or sold.